AU
UK
CA
NZ
IND
US
Last update at 2026-06-05T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -60.36600M | -28.89300M | -26.35000M |
| Minority interest | - | - | - |
| Net income | -60.36600M | -28.89300M | -26.35000M |
| Selling general administrative | 12.48M | 8.01M | 6.15M |
| Selling and marketing expenses | - | - | - |
| Gross profit | - | - | - |
| Reconciled depreciation | 1.71M | 1.05M | 0.59M |
| Ebit | - | - | - |
| Ebitda | - | - | - |
| Depreciation and amortization | - | - | - |
| Non operating income net other | - | - | - |
| Operating income | -62.40600M | -29.38400M | -26.34600M |
| Other operating expenses | - | - | - |
| Interest expense | 0.19M | 0.07M | 0.00300M |
| Tax provision | - | - | - |
| Interest income | 2.28M | 0.56M | 0.00100M |
| Net interest income | 2.10M | 0.50M | -0.00200M |
| Extraordinary items | - | - | - |
| Non recurring | - | - | - |
| Other items | - | - | - |
| Income tax expense | - | - | - |
| Total revenue | 0.00000M | 7.03M | 5.66M |
| Total operating expenses | 62.41M | 36.41M | 32.00M |
| Cost of revenue | - | - | - |
| Total other income expense net | -0.05500M | -0.00900M | -0.00200M |
| Discontinued operations | - | - | - |
| Net income from continuing ops | -60.36600M | -28.89300M | -26.35000M |
| Net income applicable to common shares | - | - | - |
| Preferred stock and other adjustments | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 75.19M | 66.92M | 85.49M |
| Intangible assets | - | - | - |
| Earning assets | - | - | - |
| Other current assets | 3.12M | 1.93M | 1.02M |
| Total liab | 206.59M | 140.92M | 131.74M |
| Total stockholder equity | -131.39700M | -73.99700M | -46.25400M |
| Deferred long term liab | - | - | - |
| Other current liab | 3.52M | 0.56M | 0.57M |
| Common stock | - | - | - |
| Capital stock | 0.00000M | 0.00000M | 0.00000M |
| Retained earnings | -136.04300M | -75.67700M | -46.78400M |
| Other liab | - | - | - |
| Good will | - | - | - |
| Other assets | - | - | - |
| Cash | 34.65M | 37.73M | 76.07M |
| Cash and equivalents | - | - | - |
| Total current liabilities | 19.86M | 11.95M | 15.93M |
| Current deferred revenue | - | - | - |
| Net debt | - | - | - |
| Short term debt | - | - | - |
| Short long term debt | - | - | - |
| Short long term debt total | - | - | - |
| Other stockholder equity | - | - | - |
| Property plant equipment | - | - | - |
| Total current assets | 60.66M | 53.25M | 77.09M |
| Long term investments | - | - | - |
| Net tangible assets | - | - | - |
| Short term investments | 22.90M | 13.59M | 0.00000M |
| Net receivables | - | - | - |
| Long term debt | - | - | - |
| Inventory | - | - | - |
| Accounts payable | 4.36M | 1.45M | 0.77M |
| Total permanent equity | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - |
| Accumulated other comprehensive income | - | - | - |
| Additional paid in capital | - | - | - |
| Common stock total equity | - | - | - |
| Preferred stock total equity | - | - | - |
| Retained earnings total equity | - | - | - |
| Treasury stock | - | - | - |
| Accumulated amortization | - | - | - |
| Non currrent assets other | 3.92M | 1.23M | 0.59M |
| Deferred long term asset charges | - | - | - |
| Non current assets total | 14.53M | 13.67M | 8.40M |
| Capital lease obligations | 9.08M | 10.56M | 5.55M |
| Long term debt total | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -8.78500M | -14.09700M | -1.28900M |
| Change to liabilities | - | - | - |
| Total cashflows from investing activities | - | - | - |
| Net borrowings | - | - | - |
| Total cash from financing activities | 58.12M | 11.88M | 72.52M |
| Change to operating activities | - | - | - |
| Net income | -60.36600M | -28.89300M | -26.35000M |
| Change in cash | -3.07700M | -38.33000M | 49.08M |
| Begin period cash flow | 38.29M | 76.62M | 27.54M |
| End period cash flow | 35.21M | 38.29M | 76.62M |
| Total cash from operating activities | -52.41000M | -36.11300M | -22.15500M |
| Issuance of capital stock | 59.90M | 11.95M | 72.53M |
| Depreciation | 1.71M | 1.05M | 0.59M |
| Other cashflows from investing activities | - | - | - |
| Dividends paid | - | - | - |
| Change to inventory | - | - | - |
| Change to account receivables | - | - | - |
| Sale purchase of stock | - | - | - |
| Other cashflows from financing activities | - | - | - |
| Change to netincome | - | - | - |
| Capital expenditures | 0.62M | 0.77M | 1.29M |
| Change receivables | - | - | - |
| Cash flows other operating | - | - | - |
| Exchange rate changes | - | - | - |
| Cash and cash equivalents changes | - | - | - |
| Change in working capital | 3.42M | -10.32700M | -4.49100M |
| Stock based compensation | 2.22M | 0.93M | 7.25M |
| Other non cash items | 1.72M | 1.41M | 0.83M |
| Free cash flow | -53.03100M | -36.88100M | -23.44400M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | ||
|---|---|---|---|---|---|---|---|---|
| KYTX Kyverna Therapeutics, Inc. Common Stock |
-0.48 6.04% | 7.47 | - | - | - | - | ||
| NVO Novo Nordisk A/S |
-0.79 1.81% | 42.96 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.6937 1.57% | 43.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.09 1.15% | 446.83 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
6.72 1.07% | 635.45 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
5980 Horton Street, Emeryville, CA, United States, 94608
| Name | Title | Year Born |
|---|---|---|
| Dr. Peter Maag Ph.D. | CEO & Director | 1967 |
| Ms. Karen Walker | Chief Technology Officer | 1962 |
| Dr. James Chung M.D., Ph.D. | Chief Medical Officer | 1968 |
| Mr. Ryan Jones | Chief Financial Officer | 1988 |
| Dr. Tom Van Blarcom Ph.D. | Senior VP & Head of Research | NA |
| Ms. Portia Serame | Vice President of Human Resources | NA |
| Dr. Dominic Borie M.D., Ph.D. | President of Research & Development | 1963 |
| Mr. Devin Murray | Senior Vice President of Partnerships & Alliances | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...